Product Development and Innovation - The company has successfully passed quality consistency evaluations for multiple generic drugs, confirming their quality and efficacy equivalent to original research drugs, which lays a solid foundation for further exploring the potential of existing products [4]. - The company has developed a range of new products targeting various therapeutic areas, including oncology and chronic diseases, enhancing its product portfolio [2]. - ASKC202 is a first-class innovative drug with independent intellectual property rights, targeting c-Met for treating non-small cell lung cancer in patients resistant to first and third-generation EGFR inhibitors [8]. - ASKG915, a dual-function fusion molecule, has shown significant anti-tumor activity in preclinical studies and is expected to fill market gaps in cancer immunotherapy [19]. - The company has developed an international leading cytokine prodrug technology platform, emphasizing innovation in drug development [9]. - The company aims to develop "First in Class" biopharmaceuticals based on its proprietary technology platforms, focusing on differentiated therapeutic approaches [17]. - The company is actively expanding its product pipeline with several innovative drug projects in various stages of clinical research [13]. - The company has 43 ongoing research projects, including 11 key innovative drugs in development such as ASK120067 tablets and injectable ASK0912 [84]. - The company has successfully licensed its Smartkine® cytokine technology platform to Xilio Therapeutics, enhancing its platform value through international collaborations [141]. - The company has developed a rich pipeline of innovative drugs, including ASK120067, a third-generation EGFR TKI for treating EGFR mutation non-small cell lung cancer, which is undergoing phase III clinical trials [164]. Market Strategy and Expansion - The company is focusing on expanding its market presence through innovative product development and strategic partnerships [4]. - The company is exploring new strategies for market expansion, including potential mergers and acquisitions to enhance its competitive edge [4]. - The company is focusing on expanding its market presence through centralized procurement, which is expected to create new market opportunities despite price pressures [76]. - The company’s subsidiaries, including AskGene and AskPharma, are involved in overseas operations to enhance its global footprint [68]. - The company plans to actively seek external collaboration and licensing opportunities to create new growth points for performance [172]. Financial Performance - The company’s revenue for the reporting period was ¥711,848,179.82, a decrease of 29.56% compared to ¥1,010,521,190.03 in the same period last year [46]. - The net profit attributable to shareholders was -¥158,452,330.29, representing a significant decline of 1,368.02% from ¥12,496,010.08 in the previous year [46]. - The net cash flow from operating activities was -¥96,141,046.79, which is a 172.97% increase in losses compared to -¥35,220,435.74 in the same period last year [46]. - The basic earnings per share were -¥0.17, a decrease of 1,800.00% from ¥0.01 in the previous year [46]. - Total assets at the end of the reporting period were ¥3,233,503,311.40, down 5.30% from ¥3,414,367,396.12 at the end of the previous year [46]. - The net assets attributable to shareholders decreased by 5.48% to ¥2,800,476,458.00 from ¥2,962,969,644.26 at the end of the previous year [46]. - The company plans not to distribute cash dividends or issue bonus shares [56]. Regulatory and Compliance - The company has maintained a strong focus on product quality, achieving GMP certification for 42 consecutive times, ensuring rigorous quality management throughout the production process [16]. - The company is committed to ensuring compliance with GMP standards to maintain product quality and safety [70]. - The company emphasizes quality management and compliance with the latest regulations, aiming to enhance product quality standards and improve market competitiveness [196]. - The company is conducting consistency evaluation work for its products, which will support their procurement in medical institutions and enhance their technical advantages [196]. Challenges and Industry Trends - The pharmaceutical industry faces significant challenges due to intensified competition and rising costs from policies promoting centralized drug procurement [51]. - The implementation of the DRG/DIP payment reform is expected to change the cost control logic of medical institutions, impacting the demand for certain drugs [54]. - The average price reduction for drugs in the eighth batch of centralized procurement was 56%, impacting the profitability of market participants [75]. - A total of 333 drug varieties have been included in the centralized procurement from the first to the eighth batch, with most major varieties being included [75]. - The new drug catalog implemented on March 1, 2023, includes 24 major innovative domestic drugs, with a negotiation success rate of 83.3% [77]. - The pharmaceutical manufacturing industry in China saw a revenue of CNY 1,249.6 billion in the first half of 2023, a year-on-year decrease of 2.9% [101]. Research and Development - R&D expenditure reached 326.90 million yuan, accounting for 45.92% of total revenue, with capitalized R&D costs making up 40.59%, a year-on-year increase of 37.80% [122]. - The company has received approval for 16 new products from 2021 to date, focusing on differentiated innovation in the fields of digestion, anti-infection, and oncology [110]. - The company has established a comprehensive new drug R&D capability covering the entire process from drug design to clinical research, prioritizing the clinical development of existing innovative drugs [156]. - The company has established multiple R&D platforms, including the SmartKine® cytokine prodrug platform, aimed at enhancing drug efficacy and reducing side effects [170]. Product Quality and Safety - The company is committed to improving patient outcomes through the introduction of advanced therapies and maintaining high standards in drug quality [4]. - The company has established a comprehensive drug safety management system to effectively manage product quality post-market [16]. - The company emphasizes a quality management goal to enhance efficiency and has implemented stricter internal quality standards beyond national regulations [184]. - The company focuses on unmet clinical needs in the anti-infection field, developing a series of products to enhance its competitive advantage [185].

Group 1: Company Overview and R&D Focus - The company, Beijing Ausun Pharmaceutical Co., Ltd., focuses on four major therapeutic areas: digestion, oncology, anti-infection, and chronic diseases [1] - The R&D investment is expected to maintain the same scale as in 2022 for the next 2-3 years, with a careful evaluation of clinical and commercial value for each project [2] - As of December 2022, the R&D team consists of 372 members, with a strong background in innovative drug development [2] Group 2: R&D Strategy and Pipeline - The company has established a clinical team of over 100 members with extensive experience in innovative drug development [3] - The R&D strategy includes internal incubation, licensing in, and business development to enhance the pipeline [3] - The small molecule pipeline includes innovative anti-tumor drugs like ASK120067, which is a third-generation EGFR TKI for NSCLC, and ASK202, a c-Met inhibitor for resistant patients [4] Group 3: Clinical Progress and Product Launches - The innovative drug ASKB589 is currently in Phase II clinical trials, with positive safety and tolerability results reported [4] - The company has a self-operated and third-party combined approach for product promotion, with over 200 members in the self-operated team [3] - Two IL-15 cytokine drugs, ASKG315 and ASKG915, are in clinical trials, with ASKG915 approved by the FDA for clinical trials in the U.S. [5]

证券代码：002755 证券简称：奥赛康 北京奥赛康药业股份有限公司 投资者关系活动记录表 编号：2023-003 投资者关系活动类 □√特定对象调研 □分析师会议 别 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 □√其他 （电话会议） 参与单位名称 天风证券：李妞妞 及人员姓名 Point72 Hong Kong Limited 分析员：李大蔚、吴雪璐 时间 2023 年 5 月 5 日 地点 电话会议 上市公司接待人员 总经理、董事会秘书 马竞飞 姓名 证券事务部长 王燕燕 一、公司基本情况介绍 介绍公司基本情况。 二、主要沟通问答 问题 1、公司小分子创新药目前有哪些布局及进展？ 投资者关系活动主 答：公司已布局多款小分子创新药，其中主要产品有抗肿瘤创 要内容介绍 新药 ASK120067 片，是第三代 EGFR TKI，用于治疗 EGFR 突变非 小细胞肺癌（NSCLC），已申报生产。同步也在开展一线用药关于 存在 EGFR 敏感突变的初诊或手术治疗后复发的局部晚期或转移性 非小细胞肺癌的Ⅲ期临床研究试验。 抗肿瘤创新药 ASKC202 片，是一种强效、高选择性的口服小分 子 c- ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥338,557,552.24, a decrease of 36.78% compared to ¥535,530,478.60 in the same period last year[18]. - The net profit for Q1 2023 was -¥75,383,018.82, representing a decline of 578.78% from a profit of ¥15,744,769.03 in the previous year[18]. - The total comprehensive income attributable to the parent company was -¥64,219,728.17, compared to ¥21,168,998.78 in the previous year[4]. - The total comprehensive income for the period was -¥69,360,660.14, contrasting with a positive figure of ¥17,869,761.02 in the previous year[4]. - Net profit attributable to shareholders of the listed company was -¥68,591,234.11, a decline of 454.23% from ¥19,363,474.87 in the previous year[28]. - Basic and diluted earnings per share were both -¥0.07, a decrease of 450.00% compared to ¥0.02 in the previous year[28]. Cash Flow - The net cash flow from operating activities was -¥110,779,210.22, a significant decrease of 665.11% compared to ¥19,603,258.69 in the same period last year[18]. - The net cash flow from operating activities was negative at -¥110,779,210.22, compared to a positive ¥19,603,258.69 in the previous period[40]. - Investment activities generated a net cash flow of ¥64,925,880.98, a significant improvement from a negative cash flow of -¥309,240,973.28 in the prior period[40]. - The cash outflow for operating activities totaled ¥514,876,351.57, compared to ¥668,515,802.93 in the previous period, showing a reduction of about 23.1%[40]. Expenses - Research and development expenses increased by 33.32% to ¥122,347,542.93, driven by ongoing investments in innovative and biological drug development[18]. - The company's sales expenses decreased by 36.84% to ¥214,979,509.61, reflecting the decline in revenue[18]. - Operating costs for the quarter were ¥66,056,085.50, compared to ¥62,513,029.96 in the previous year[24]. - The company reported a total operating cost of ¥431,430,413.60, down from ¥522,904,935.40 in the same period last year[24]. - The company experienced a significant increase in credit impairment losses, totaling ¥483,515.78 compared to ¥1,828,840.71 in the previous year[25]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3,343,052,135.42, a decrease of 2.09% from ¥3,414,367,396.12 at the end of the previous year[28]. - The total liabilities amounted to ¥398,340,507.37, a slight decrease from ¥401,028,107.04 in the previous period, indicating a reduction of approximately 0.4%[36]. - Non-current liabilities totaled ¥87,558,087.12, up from ¥77,285,435.67, reflecting an increase of about 13.6%[36]. - The company's total equity was ¥2,944,711,628.05, a decrease from ¥3,013,339,289.08, reflecting a decline of approximately 2.3%[36]. Shareholder Information - The company had a total of 22,075 common shareholders at the end of the reporting period[19]. Inventory and Compensation - The company's inventory increased to ¥158,779,979.08 from ¥141,533,272.91, marking an increase of approximately 12.2%[43]. - The company reported a decrease in employee compensation payable to ¥15,450,807.12 from ¥41,419,835.05, a reduction of about 62.7%[43].

Financial Performance - The company reported a total revenue of 1.2 billion RMB for the year 2022, representing a year-on-year increase of 15%[13]. - The net profit attributable to shareholders was 300 million RMB, which is a 10% increase compared to the previous year[13]. - The company's operating revenue for 2022 was ¥1,872,572,189.84, a decrease of 39.72% compared to ¥3,106,666,569.36 in 2021[19]. - The net profit attributable to shareholders for 2022 was -¥225,825,439.44, representing a decline of 159.44% from ¥379,907,787.30 in 2021[19]. - The net cash flow from operating activities was -¥52,814,933.61 in 2022, down 109.30% from ¥567,707,650.56 in 2021[19]. - The total assets at the end of 2022 were ¥3,414,367,396.12, an 8.33% decrease from ¥3,724,750,010.48 at the end of 2021[19]. - The net assets attributable to shareholders decreased by 7.94% to ¥2,962,969,644.26 at the end of 2022 from ¥3,218,681,536.00 at the end of 2021[19]. - The basic earnings per share for 2022 was -¥0.24, a decline of 158.54% from ¥0.41 in 2021[19]. - The company reported a weighted average return on equity of -7.29% in 2022, down from 12.53% in 2021[19]. - The company achieved a revenue of CNY 1,872.57 million in 2022, a decrease of 39.72% year-on-year[56]. - The net profit attributable to shareholders was CNY -225.83 million, significantly impacted by a price drop of over 90% for 12 products selected in national centralized procurement[56]. Research and Development - Research and development expenses increased by 25% in 2022, totaling 150 million RMB, to support new product innovation[13]. - R&D investment reached CNY 722.97 million, accounting for 38.61% of total revenue, an increase of 74.58% year-on-year[57]. - The company has 43 projects in development, including 11 key innovative drugs such as ASK120067 and ASKG915[47]. - Six innovative drug clinical approvals were obtained during the reporting period, including ASKC202 and ASK0912[48]. - The company has submitted 469 patent applications, with 240 patents granted, including 174 Chinese invention patents[53]. - The company is focusing on high-barrier complex formulations and innovative drug development in oncology and chronic disease treatment[47]. - The company has established a national enterprise technology center and has been recognized as a national technology innovation demonstration enterprise[39]. - The company has launched a total of 15 products since 2021, including Posaconazole Injection and Dexamethasone Injection[45]. - The company is actively involved in research and development, with several projects in the pipeline[46]. - The company aims to enhance its innovation capabilities by focusing on small molecule targeted innovative drug development and expanding into tumor immunotherapy[151]. Market Expansion and Strategy - The company plans to launch three new products in 2023, focusing on innovative drug development and targeting a market size of 500 million RMB[13]. - Future guidance indicates a projected revenue growth of 20% for 2023, aiming for a total revenue of 1.44 billion RMB[13]. - The company is expanding its market presence in Southeast Asia, with plans to enter two new countries by the end of 2023[13]. - The company is actively exploring acquisition opportunities to expand its product portfolio and market reach[13]. - A strategic acquisition of a smaller pharmaceutical company is planned, which is expected to enhance the company's product portfolio and increase revenue by 200 million RMB annually[196]. - The company is expanding its digital marketing efforts by collaborating with third-party platforms such as Tmall and JD.com to enhance patient access to medications[100]. - The company is focusing on expanding its market presence through innovative drug development and strategic partnerships[120]. - The company aims to enhance its market presence through strategic product launches and expanding its therapeutic areas[44]. - The company is actively expanding its market presence through academic promotion activities and participation in large-scale exhibitions to increase brand awareness and market share[63]. Product Development and Innovation - The company focuses on the development of innovative drugs and high-tech generic drugs, with a strong presence in digestive, anti-tumor, anti-infection, and chronic disease treatment areas[38]. - The company has developed new products such as the Mesna Injection and the Erlotinib Capsule, expanding its oncology portfolio[45]. - The company’s products are designed to address unmet medical needs, particularly in oncology and chronic disease management[44]. - The company has launched a range of anti-infection products, including polymyxin E and posaconazole, to address the growing issue of antibiotic resistance[80]. - The company has introduced the first approved injectable Polymyxin E sulfate, which is critical for treating multi-drug resistant Gram-negative bacterial infections, especially in children[83]. - The company has successfully launched Lenvatinib capsules, breaking a decade-long monopoly in first-line treatment for liver cancer[88]. - The company has introduced Temozolomide injection, becoming the second domestic company to obtain approval for this innovative anti-tumor drug[89]. - The company is committed to high-quality development amidst economic challenges, enhancing overall management levels[96]. - The company aims to enhance product quality and market competitiveness through consistency evaluation, aligning with international standards[95]. Governance and Management - The company has established a complete independent business operation system, demonstrating autonomous management capabilities without reliance on the controlling shareholder[179]. - The company maintains an independent personnel management system, ensuring that all senior management personnel are exclusively employed by the company and do not hold positions in the controlling shareholder's enterprises[180]. - The company has a robust governance structure with a clear separation of powers among the shareholders' meeting, board of directors, and supervisory board, ensuring effective checks and balances[182]. - The company has an independent financial department and internal audit team, establishing a standardized accounting system and independent financial decision-making capabilities[183]. - The company is focused on sustainable development through its "health-based innovation" management model[189]. - The company has a new management team with key appointments including Ma Jingfei as the general manager and board secretary[188]. - The company is committed to maintaining a strong leadership team to drive future growth and innovation[188]. Challenges and Risks - The company has faced uncertainty regarding its ability to continue as a going concern, as indicated by the negative net profits over the last three accounting years[19]. - The company faces ongoing sales pressure due to national centralized procurement policies, leading to an average price drop of over 80% for proton pump inhibitors (PPIs)[156]. - The company has shifted to larger packaging to reduce costs, impacting sales and production volumes across several product lines[110]. - The company has experienced changes in its supervisory board, with new appointments made in 2022[188]. - The company has faced increased competition in 2022, particularly affecting the sales of "Aonoxian" due to the introduction of competing products[112]. Future Outlook - The company has set a future outlook with a revenue target of 1.8 billion RMB for 2023, indicating a projected growth of 20%[196]. - The company is investing in new technology for drug development, with a budget allocation of 100 million RMB for R&D in 2023[196]. - The management has implemented new strategies to improve operational efficiency, aiming for a 5% reduction in costs by the end of 2023[196]. - The company aims to enhance its competitive edge by diversifying its product offerings in the oncology sector with new drug approvals expected in the near future[120].

本公司及董事会全体成员保证信息披露内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 证券代码：002755 证券简称：奥赛康 公告编号：2023-017 北京奥赛康药业股份有限公司 关于举行 2022 年度网上业绩说明会的公告 北京奥赛康药业股份有限公司董事会 2023 年 4 月 28 日 北京奥赛康药业股份有限公司（以下简称"公司"）将于 2023 年 5 月 12 日 （星期五）下午 15：00—17：00 在全景网举办 2022 年度业绩说明会，本次年度 业绩说明会将采用网络远程的方式举行，投资者可登陆"全景•路演天下" （http://rs.p5w.net）参与本次年度业绩说明会。 出席本次说明会的人员有：公司董事长陈庆财先生，董事、总经理、董事会 秘书马竞飞先生，独立董事吴晓明先生、财务总监韩涛先生，以及公司其他相关 人员。 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业绩说明会提 前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 5 月 12 日（星期五）中午 12:00 前访问 http://ir.p5w.net/zj/，或扫描下方二维码 ...

北京东方新星石化工程股份有限公司 投资者关系活动记录表 编号：2015-001 | --- | --- | |-------------------|------------------------------------------------------------------------------------------------------| | | | | | □ 特定对象调研 | | | ☑ 分析师会议 | | 投资者关系 活 | □ 媒体采访 | | 动类别 | □ 业绩说明会 | | | □ 新闻发布会 | | | □ 路演活动 | | | □ 现场参观 | | 参 与 单 位 名 称 | □其他（请文字说明其他活动内容） 广发证券—岳恒宇、唐笑、沈振豪；安信证券—夏天、程龙戈； 国海证券—王鑫 | | 及人员姓名 | | | 时间 | 2015 年 11 月 10 日 14:00-16:30 | | --- | --- | |---------------|----------------------------------------------------------------| ...

北京东方新星石化工程股份有限公司 投资者关系活动记录表 编号：2015-005 | --- | --- | |-----------------|------------------------------------------------------------| | | | | | □ 特定对象调研 | | | ☑ 分析师会议 | | 投 资 者 关 系 | □ 媒体采访 | | 活动类别 | □ 业绩说明会 | | 参与单位名 称 | 民生证券—严晓情 | | 及人员姓名 时间 | 9:30-10:30 | | 地点 | 北京市丰台区南四环西路 188 号七区五 8 号七楼会议室 | | 上 市 公 司 接 | 胡德新（董秘）、路忠（证代） | | 待人员姓名 | | | --- | --- | |-----------------|---------------------------------------------------------------------------------------------------------------------------------------- ...